Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients

European Journal of Clinical Pharmacology

Volumn 68, Issue 4, 2012, Pages 415-418

  Gupta, Samir K ^a   Kantesaria, Bhavna ^a   Glue, Paul ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hemodialysis; Pharmacokinetics; Ribavirin

Indexed keywords

DIURETIC AGENT; ERYTHROPOIETIN; PHOSPHATE BINDING AGENT; RIBAVIRIN; VITAMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY EXCRETION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RIBAVIRIN;

EID: 84860310793     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1137-x     Document Type: Article

References (15)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB,Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-Dribofuranosyl- 1,2,4-triazole-3-carboxamide. Science 177:705-706
2. Martin P, Jensen DM (2008) Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 23:844-855 (Pubitemid 351806583)
3. Glue P (1999) The clinical pharmacology of ribavirin. Semin Liver Dis 19 [Suppl 1]:17-24 (Pubitemid 29220816)
4. Glue P, Tan Y, Sack M, Schencker S, Zambas D, Gupta SK (1999) Use of ribavirin in special populations-pharmacokinetic data and biological relevance. Hepatology 30:309A
5. Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M (2000) The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 49:417-421 (Pubitemid 30229444)
6. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York, pp 409-417
7. Data on File. Merck Research Laboratory, Kenilworth, NJ
8. Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD (1990) Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother 34:489-490 (Pubitemid 20068680)
9. Singlas E, Taburet F, Lebas B, De Curzon OP, Sobel A, Chauveau P, Viron B, Khayat RA, Poignet JL, Mignon F, Humbert G, Fillastre JP (1992) Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrob Agents Chemother 36:1519-1524
10. Singlas E, Pioger JC, Taburet AM, Colin JN, Fillastre JP (1989) Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 46:190-197 (Pubitemid 19219956)
11. Copegus" prescribing information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021511s023lbl.pdf. Accessed 14 September 11
12. Tan ACTTL, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B (2001) Safety of interferon and ribavirin therapy in hemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 16:193-195 (Pubitemid 32051512)
13. Bruchfeld A, Stahle L, Andersson J, Schvarcz R (2001) Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 8:287-292 (Pubitemid 32673741)
14. Van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ (2008) Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 23:721-725 (Pubitemid 351767641)
15. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, Schena FP, Di Leo A, Francavilla A (2007) The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46:768-774 (Pubitemid 46529043)